Out-of-pocket costs for AstraZeneca and Boehringer Ingelheim inhalers will be capped at $35 per month beginning in June, the drugmakers recently announced in separate statements. GlaxoSmithKline said it will implement a $35 cap by the end of...
Out-of-pocket costs for AstraZeneca and Boehringer Ingelheim inhalers will be capped at $35 per month beginning in June, the drugmakers recently announced in separate statements. GlaxoSmithKline said it will implement a $35 cap by the end of...
Out-of-pocket costs for...